Results 211 to 220 of about 101,548 (353)

Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States. [PDF]

J Manag Care Spec Pharm
Akpan N, Zhou B, Rasu RS, Sambamoorthi U.   +3 more
europepmc   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Use Does Not Impact Spine Surgery Outcomes: A Systematic Review and Meta-Analysis. [PDF]

Global Spine J
Ibrahim S, Durrani A, Ibrahim MT, Kuttner N, Glivar P, Singh VK, Yu E.   +6 more
europepmc   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Revolutionizing Diabetes and Obesity Management: A Comprehensive Review of Tirzepatide’s Dual Agonist Approach

JK Science
Tirzepatide, an innovative glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, has emerged as a promising therapeutic avenue for type 2 diabetes and obesity management.
Sonam Samal, Sourav Maiti, Jonnalagadda Vihari   +2 more
doaj  

Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents. [PDF]

Diabetes Metab J
Wang SY, Stofer R, Wang H, Brent GA, Shi L, Cai Y, Roosan M, Moin T.   +7 more
europepmc   +1 more source

A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

Science Translational Medicine, 2017
H. Botfield, M. Uldall, C. Westgate, J. Mitchell, S. Hagen, A. González, D. Hodson, R. Jensen, A. Sinclair   +8 more
semanticscholar   +1 more source

Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy

Epilepsia, EarlyView.
Abstract Objective To examine whether initiation of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes. Methods We conducted a retrospective cohort study using de‐identified electronic health records from the TriNetX Research Network (January 2003 ...
Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua   +5 more
wiley   +1 more source

Methodological and statistical errors distort the effects of glucagon-like peptide-1 receptor agonist drugs on body composition in patients with type 2 diabetes mellitus. [PDF]

Diabetol Metab Syndr
Trexler ET.
europepmc   +1 more source

Artificial lipidation of proteins and peptides: from mechanism to clinical applications

The FEBS Journal, EarlyView.
Artificial lipidation transforms protein and peptide therapeutics by attaching fatty acid chains through reversible or permanent chemical strategies. This biomimetic approach delivers four key therapeutic advantages: extended circulation times (enabling weekly instead of daily dosing), alternative administration routes including oral delivery, precise ...
Jiaming Mu, Emily Vong, Sheiliza Carmali
wiley   +1 more source